Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Cash from Financing Activities (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Cash from Financing Activities for 3 consecutive years, with $13.7 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 97.0% to $13.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.5 million through Dec 2025, down 95.52% year-over-year, with the annual reading at $29.5 million for FY2025, 95.52% down from the prior year.
  • Cash from Financing Activities hit $13.7 million in Q4 2025 for NewAmsterdam Pharma, up from $5.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $456.6 million in Q4 2024 to a low of $58000.0 in Q3 2024.
  • Historically, Cash from Financing Activities has averaged $63.4 million across 3 years, with a median of $5.9 million in 2025.
  • Biggest YoY gain for Cash from Financing Activities was 10058.62% in 2025; the steepest drop was 97.0% in 2025.
  • Year by year, Cash from Financing Activities stood at $186000.0 in 2023, then soared by 245389.78% to $456.6 million in 2024, then tumbled by 97.0% to $13.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for NAMS at $13.7 million in Q4 2025, $5.9 million in Q3 2025, and $3.4 million in Q2 2025.